Back to products

Capivast 200 mg Tablet

Brand Name: Capivast

Molecule: Capivasertib

Strength: 200 mg

Quantity: 64 Tablets

Form: Tablet

Packaging Type: Bottle

Manufacturer/Marketed By: Everest Pharma

Country of Origin: Bangladesh

Image	Product	Manufacturer / Marketed By	Price
	Truqap 200 mg Tablet	Astrazeneca	Ask for Price
	LuciCapiva 200 mg Tablet	Lucius Pharma	Ask for Price

Description

Capivast 200 mg Tablet contains capivasertib, an oral targeted anticancer medicine classified as an AKT kinase inhibitor. It is used in certain types of advanced or metastatic breast cancer, particularly hormone receptor (HR)-positive and HER2-negative disease with specific genetic alterations in the PI3K/AKT/PTEN pathway. Capivasertib is typically prescribed in combination with other oncology medicines, such as endocrine therapy, depending on the treatment plan recommended by a qualified healthcare professional. Capivasertib works by inhibiting AKT, a key enzyme involved in cell signaling pathways that regulate tumor cell growth, survival, and metabolism. Abnormal activation of the AKT pathway can contribute to cancer progression. By blocking this pathway, the medicine may help slow tumor growth in certain patients when used as prescribed and under medical supervision. Treatment with Ca

Benefits

Targets the AKT signaling pathway, which plays a role in cancer cell survival and growth
Part of a precision oncology approach based on tumor molecular characteristics
Oral tablet formulation suitable for outpatient treatment
May help slow disease progression in certain patients with HR-positive metastatic breast cancer
Often used in combination with other anticancer therapies for improved treatment strategies

Indications and Usage

Capivast (capivasertib) may be prescribed for:

Hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer
Patients with PI3K/AKT/PTEN pathway alterations
Use in combination with endocrine therapy (such as fulvestrant) when recommended by an oncologist
Situations where disease has progressed after prior endocrine therapy

Use is determined by a healthcare professional based on tumor characteristics, genetic testing results, and clinical guidelines.

How it Works

Capivasertib works by inhibiting AKT (protein kinase B), a key component of the PI3K/AKT/mTOR signaling pathway that regulates cell growth, survival, and metabolism. In certain cancers, genetic changes in this pathway can lead to uncontrolled cell proliferation and resistance to standard therapies.

By blocking AKT activity, capivasertib disrupts signals that allow cancer cells to grow and survive. This targeted mechanism may help slow tumor progression, particularly in cancers with PIK3CA, AKT1, or PTEN alterations, when used as prescribed and monitored by a healthcare professional.

Dosage & Administration

Capivast tablets are taken orally, typically in cycles as directed by a healthcare professional.
Tablets should be swallowed whole with water.
Do not crush, split, or chew the tablets.
The medicine may be taken with or without food, unless directed otherwise.
Dosage schedules and duration depend on clinical response, tolerance, and physician guidance.
Regular monitoring may be required during treatment.

Side Effects

Common side effects

Diarrhea
Rash or skin reactions
Nausea
Fatigue
Decreased appetite
Increased blood glucose levels

Serious side effects

Severe diarrhea or dehydration
Significant skin reactions
High blood sugar (hyperglycemia)
Severe infections
Allergic reactions

Patients should report unusual or severe symptoms to their healthcare provider promptly.

Warning and Precaution

Risk of severe diarrhea and dehydration
Possible skin reactions or rash
Risk of hyperglycemia (high blood sugar)
Potential infections due to immune system effects
May cause fetal harm during pregnancy
Inform healthcare providers about all medications and supplements before starting treatment
Use caution in patients with pre-existing metabolic or endocrine conditions

Patient Guidance

Take the medicine exactly as prescribed by your oncologist
Attend scheduled medical appointments and laboratory tests
Report symptoms such as severe diarrhea, rash, or high blood sugar
Inform your healthcare provider about all other medications or supplements
Maintain adequate hydration during treatment
Do not change or stop treatment without medical advice

Clinical Trial & Approvals

Capivasertib has been evaluated in several clinical trials investigating its effectiveness in advanced breast cancer with PI3K/AKT/PTEN pathway alterations. Studies such as the CAPItello-291 trial evaluated capivasertib in combination with endocrine therapy in patients with HR-positive, HER2-negative advanced breast cancer. Regulatory approvals have been granted in some regions based on these clinical trial results, with ongoing research continuing to explore additional therapeutic uses.

References

U.S. Food and Drug Administration (FDA) – Capivasertib Drug Information
https://www.fda.gov
European Medicines Agency (EMA) – Oncology Medicines Database
https://www.ema.europa.eu
National Cancer Institute – Targeted Cancer Therapies
https://www.cancer.gov
ClinicalTrials.gov – Studies Evaluating Capivasertib
https://clinicaltrials.gov
Drugs.com – Capivasertib Drug Information
https://www.drugs.com
CAPItello-291 Clinical Trial Publication
https://clinicaltrials.gov/study/NCT04305496

Capivast 200 mg Tablet is generally supplied against a valid prescription. For international orders, patients may need to provide documentation such as a licensed physician’s prescription, identification, and country-specific import paperwork, depending on local regulations. MedsMonk can assist with documentation guidance where applicable.

FAQ

What is Capivast 200 mg Tablet used for?+

Capivast is used in certain patients with advanced hormone receptor–positive, HER2-negative breast cancer, particularly when specific genetic pathway alterations are present.

What is the active ingredient in Capivast?+

The active ingredient is capivasertib, an AKT kinase inhibitor.

Is Capivast chemotherapy?+

Capivast is considered a targeted therapy, not traditional chemotherapy.

Is Capivast taken alone or with other medicines?+

It is often prescribed in combination with endocrine therapy, depending on the patient’s treatment plan.

Do I need a prescription to buy Capivast?+

Yes. Capivast is a prescription-only oncology medicine.

Can Capivast affect blood sugar levels?+

Yes. Some patients may experience increased blood glucose levels, which should be monitored during treatment.

What should I do if I experience severe diarrhea?+

Contact your healthcare provider promptly, as severe diarrhea may require medical management.

How should Capivast tablets be stored?+

Store at room temperature, away from moisture and excessive heat, unless otherwise directed.

Ruxolitinib Tablets Receive FDA Approval for Hematologic Malignancies

The U.S. Food and Drug Administration (FDA) has approved Ruxolitinib tablets for the treatment of certain hematologic malignancies, marking another

May 18, 2026

Tovorafenib Approved in Europe for Children with BRAF-Altered Low-Grade Glioma

n Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 14, 2026.n n This marks an important

May 14, 2026

FDA Approves Vepdegestrant for ER+/HER2–, ESR1-Mutated Breast Cancer: A New Targeted Option

Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 6, 2026. Breast cancer treatment continues to evolve

May 6, 2026

Rated 0 out of 5

0 reviews

Rated 5 out of 5

Rated 4 out of 5

Rated 3 out of 5

Rated 2 out of 5

Rated 1 out of 5

Reviews

Clear filters

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.